Stock Scorecard



Stock Summary for HUTCHMED (China) Ltd (HCM) - $16.75 as of 11/20/2024 4:09:29 PM EST

Total Score

12 out of 30

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for HCM

Positive earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for HCM

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for HCM

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for HCM

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for HCM (28 out of 90)

Stock Price Rating (Max of 10) 6
Historical Stock Price Rating (Max of 10) 8
Stock Price Trend (Max of 10) 2
Book Value (Max of 10) 1
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 5
Analyst Strong Buy Ratings (Max of 5) 3
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 3
Price to Earnings (Max of 10) 0

Latest News for for HCM

Williams-Sonoma, Wix.com, Dolby Laboratories And Other Big Stocks Moving Higher On Wednesday - Azenta ( NASDAQ:AZTA ) , Alignment Healthcare ( NASDAQ:ALHC ) 11/20/2024 3:25:00 PM
HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee - HUTCHMED ( China ) ( NASDAQ:HCM ) 11/20/2024 9:30:00 AM
HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee 11/20/2024 9:30:00 AM
HUTCHMED Highlights Clinical Data to be Presented at the 2024 ASH Annual Meeting and the 2024 ESMO Asia Congress 11/6/2024 4:00:00 AM
HUTCHMED Highlights Clinical Data to be Presented at the 2024 ASH Annual Meeting and the 2024 ESMO Asia Congress - HUTCHMED ( China ) ( NASDAQ:HCM ) 11/6/2024 4:00:00 AM
HUTCHMED to Receive First Commercial Milestone Payment Following Over US$200 Million in FRUZAQLA® ( fruquintinib ) Sales by Takeda 10/31/2024 8:30:00 AM
HUTCHMED to Receive First Commercial Milestone Payment Following Over US$200 Million in FRUZAQLA® ( fruquintinib ) Sales by Takeda - HUTCHMED ( China ) ( NASDAQ:HCM ) 10/31/2024 8:30:00 AM
HUTCHMED Announces that TAGRISSO® plus ORPATHYS® demonstrated high, clinically meaningful response rate in lung cancer patients with high levels of MET overexpression and/or amplification in SAVANNAH Phase II trial 10/16/2024 4:30:00 AM
HUTCHMED Announces Japan Approval for FRUZAQLA® ( fruquintinib ) Received by Takeda 9/24/2024 7:00:00 AM
HUTCHMED Announces Japan Approval for FRUZAQLA® ( fruquintinib ) Received by Takeda - HUTCHMED ( China ) ( NASDAQ:HCM ) 9/24/2024 7:00:00 AM

Financial Details for HCM

Company Overview

Ticker HCM
Company Name HUTCHMED (China) Ltd
Country USA
Description HUTCHMED (China) Limited discovers, develops and markets targeted immunotherapies and therapies for cancer and immune diseases globally. The company is headquartered in Central, Hong Kong.
Sector Name LIFE SCIENCES
Industry Name PHARMACEUTICAL PREPARATIONS
Most Recent Quarter 6/30/2024
Next Earnings Date N/A

Stock Price History

Last Day Price 16.75
Price 4 Years Ago 32.02
Last Day Price Updated 11/20/2024 4:09:29 PM EST
Last Day Volume 94,522
Average Daily Volume 94,055
52-Week High 21.92
52-Week Low 11.93
Last Price to 52 Week Low 40.40%

Valuation Measures

Trailing PE N/A
Industry PE 22.60
Sector PE 40.32
5-Year Average PE -18.61
Free Cash Flow Ratio 14.08
Industry Free Cash Flow Ratio 12.03
Sector Free Cash Flow Ratio 27.97
Current Ratio Most Recent Quarter 2.81
Total Cash Per Share 1.19
Book Value Per Share Most Recent Quarter 0.87
Price to Book Ratio 3.87
Industry Price to Book Ratio 5.31
Sector Price to Book Ratio 20.88
Price to Sales Ratio Twelve Trailing Months 4.69
Industry Price to Sales Ratio Twelve Trailing Months 11.82
Sector Price to Sales Ratio Twelve Trailing Months 7.11
Analyst Buy Ratings 8
Analyst Strong Buy Ratings 1

Share Statistics

Total Shares Outstanding 170,928,000
Market Capitalization 2,863,044,000
Institutional Ownership N/A

Dividends

Ex-Dividend Date N/A
Last Dividend Amount 0.00
Current Dividend Amount 0.00
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY -84.20%
Annual Earnings Growth 124.57%
Reported EPS 12 Trailing Months -0.25
Reported EPS Past Year 0.97
Reported EPS Prior Year -2.68
Net Income Twelve Trailing Months 160,466,500
Net Income Past Year 100,780,000
Net Income Prior Year -410,139,000
Quarterly Revenue Growth YOY -42.60%
5-Year Revenue Growth 31.38%
Operating Margin Twelve Trailing Months -0.09

Balance Sheet

Total Cash Most Recent Quarter 203,953,000
Total Cash Past Year 283,589,000
Total Cash Prior Year 313,278,000
Net Cash Position Most Recent Quarter 155,764,000
Net Cash Position Past Year 235,400,000
Long Term Debt Past Year 48,189,000
Long Term Debt Prior Year 18,104,000
Total Debt Most Recent Quarter 48,189,000
Equity to Debt Ratio Past Year 0.94
Equity to Debt Ratio Most Recent Quarter 0.94
Total Stockholder Equity Past Year 730,541,000
Total Stockholder Equity Prior Year 610,367,000
Total Stockholder Equity Most Recent Quarter 740,084,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months 43,383,000
Free Cash Flow Per Share Twelve Trailing Months 0.25
Free Cash Flow Past Year 186,646,000
Free Cash Flow Prior Year -305,263,000

Options

Put/Call Ratio 0.00
Has Options Options Chain
Liquidity Rating None

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD -0.68
MACD Signal -0.40
20-Day Bollinger Lower Band 15.95
20-Day Bollinger Middle Band 18.58
20-Day Bollinger Upper Band 21.21
Beta 0.75
RSI 28.68
50-Day SMA 17.62
150-Day SMA 16.08
200-Day SMA 20.35

System

Modified 11/21/2024 2:38:32 AM EST